SCHEMBL4593012

SCHEMBL4593012

Cc1cc(C#N)ccc1NS(C)(=O)=O

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TNIK Q9UKE5 1/20 0.48
SLC22A12 Q96S37 2/20 0.48
PARP14 Q460N5 1/20 0.45
NR3C1 P04150 3/20 0.44
KEAP1 Q14145 1/20 0.43
NFE2L2 Q16236 1/20 0.43
RXFP1 Q9HBX9 1/20 0.42
CRBN Q96SW2 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
PGR P06401 4/20 0.39
TBXA2R P21731 4/20 0.39
MAPT P10636 1/20 0.38
NR3C2 P08235 2/20 0.38
AR P10275 1/20 0.38
BRD4 O60885 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4641810 0.81 SLC22A12 (0.54) TNIKSLC22A12PARP14NR3C1CA1
SCHEMBL6389949 0.81 SLC22A12 (0.47) TNIKSLC22A12PARP14NR3C1CA1
SCHEMBL2005491 0.81 SLC22A12 (0.47) SLC22A12PARP14NR3C1PGR
SCHEMBL21865747 0.80 RXFP1 (0.55) SLC22A12RXFP1CRBNPGRMAPT
SCHEMBL9340013 0.79 PARP14 (0.48) TNIKSLC22A12PARP14NR3C1KEAP1
SCHEMBL12060800 0.79 SLC22A12 (0.45) TNIKSLC22A12PARP14NR3C1CA1
SCHEMBL9340017 0.78 ADRA2A (0.51) SLC22A12PARP14NR3C1CA1CA2
SCHEMBL29467983 0.78 ACLY (0.52) SLC22A12PARP14NR3C1CA1CA2
SCHEMBL897113 0.78 PARP14 (0.47) TNIKSLC22A12PARP14NR3C1CA1
SCHEMBL10208423 0.78 ACLY (0.52) SLC22A12PARP14NR3C1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227995-A1 Process of Sulfonating 4-Aminobenzonitriles SCHWARZ PHARMA AG (DE) 2008-09-18 US disclosed
US-20080227995-A1 Process of Sulfonating 4-Aminobenzonitriles SCHWARZ PHARMA AG (DE) 2008-09-18 US disclosed
US-20080227995-A1 Process of Sulfonating 4-Aminobenzonitriles SCHWARZ PHARMA AG (DE) 2008-09-18 US disclosed
EP-1910280-A2 PROCESS OF SULFONATING 4-AMINOBENZONITRILES SCHWARZ PHARMA AG (DE) 2008-04-16 EP disclosed
WO-2007009798-A2 PROCESS OF SULFONATING 4-AMINOBENZONITRILES SCHWARZ PHARMA AG (DE) 2007-01-25 WO disclosed
WO-2007009798-A2 PROCESS OF SULFONATING 4-AMINOBENZONITRILES SCHWARZ PHARMA AG (DE) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227995-A1 Process of Sulfonating 4-Aminobenzonitriles STS, ARSA, CYP2S1 TNIK 2878/4885SLC22A12 2305/4885PARP14 2413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.